# EDGAR Filing Document

**Accession Number:** 0001628171
**File Stem:** 0001610717-26-000216
**Filing Date:** 2026-6
**Character Count:** 10251
**Document Hash:** fbed3865e880521a9cd7d18687d77638
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610717-26-000216.hdr.sgml**: 20260615

**ACCESSION NUMBER**: 0001610717-26-000216

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260611

**FILED AS OF DATE**: 20260615

**DATE AS OF CHANGE**: 20260615

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Horn Margaret A
- **CENTRAL INDEX KEY:** 0001294192

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39219
- **FILM NUMBER:** 261090796

**MAIL ADDRESS:**
- **STREET 1:** 925 PAGE MILL ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Revolution Medicines, Inc.
- **CENTRAL INDEX KEY:** 0001628171
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472029180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 700 SAGINAW DR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-481-6801

**MAIL ADDRESS:**
- **STREET 1:** 700 SAGINAW DR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Horn Margaret A<br><sub>(Last) (First) (Middle)</sub><br>C/O REVOLUTION MEDICINES, INC.<br>700 SAGINAW DRIVE<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-06-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Operating Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Revolution Medicines, Inc. [ RVMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-06-11 |  | M<sup>(1)</sup> |  | 1094 | A | $42.45 | 159316<sup>(2)(3)</sup> | D |  |
| Common Stock | 2026-06-11 |  | M<sup>(1)</sup> |  | 8906 | A | $40.74 | 168222<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 1315 | D | 144.2793<sup>(4)</sup> | 166907<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 885 | D | 145.1495<sup>(5)</sup> | 166022<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 700 | D | 146.0371<sup>(6)</sup> | 165322<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 500 | D | 147.272<sup>(7)</sup> | 164822<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 1800 | D | 148.7231<sup>(8)</sup> | 163022<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 4600 | D | 149.6429<sup>(9)</sup> | 158422<sup>(2)</sup> | D |  |
| Common Stock | 2026-06-11 |  | S<sup>(1)</sup> |  | 200 | D | $150.17 | 158222<sup>(2)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $42.45 | 2026-06-11 |  | M<sup>(1)</sup> |  |  | 1094 | 2023-08-09 | 2031-03-03 | Common Stock | 1094 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $40.74 | 2026-06-11 |  | M<sup>(1)</sup> |  |  | 8906 | <sup>(10)</sup> | 2035-02-28 | Common Stock | 8906 | $0 | 91194 | D |  |

---

### Footnotes:

(1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.

(2) Includes 73,050 restricted stock units.

(3) Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

(4) This transaction was executed in multiple trades in prices ranging from $143.78 to $144.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(5) This transaction was executed in multiple trades in prices ranging from $144.79 to $145.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(6) This transaction was executed in multiple trades in prices ranging from $145.88 to $146.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(7) This transaction was executed in multiple trades in prices ranging from $147.06 to $147.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(8) This transaction was executed in multiple trades in prices ranging from $148.14 to $149.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(9) This transaction was executed in multiple trades in prices ranging from $149.17 to $150.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

(10) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

**Signature:** /s/ Jack Anders, as Attorney-in-fact for Margaret Horn  
**Date:** 2026-06-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**